About US
Contact us
-
Sun Pharma obtains US FDA approval for BromSiteThe US Food and Drug Administration (FDA) has given its approval for Sun Pharma's eye inflammation drug BromSite (bromfenac ophthalmic solution). BromSite is the first non-steroidal anti-inflammatory2016/4/12
-
Deals this week: Cutis Pharma, Sorrento Therapeutics, Yinnan Baiyao GroupCutis Pharmahas entered a joint development agreement with Dr Reddy's Laboratories for the supply of active pharmaceutical ingredients (API). The partnership enables Cutis Pharma to develop worldwide2016/4/12
-
Pfizer investors stand with CEO Read even though he is 0 for 2 on megamergersRead given credit for remaking Pfizer and investors don't blame him for miss on Allergan Pfizer ($PFE) CEOIan Readwalked away from its $160 billion merger with Allergan ($AGN) this week after U.S.Tre2016/4/11
-
Novo makes inroads in Japan with long-acting insulin TresibaNovo Nordisk ($NVO) didn't know how fraught its path would be withTresibain 2012, when it won Japanese approval for the drug. The company built up Tresiba in the country even as approval in the U.S. w2016/4/11
-
GSK Consumer Healthcare inaugurates new facility in USGSK Consumer Healthcare has inaugurated a new facility in Warren, New Jersey, US, which will employ nearly 900 people. The facility has been opened as part of a joint venture between GSK and Novartis2016/4/8
-
Novo Nordisk to Attend BioProcess International European SummitNovo Nordisk will be attending the BioProcess International European Summit from 12-13 April in Vienna, Austria. If visitors are looking to optimise cell density and viability, insulin might play an2016/4/8
-
Don't worry, Pfizer and Allergan. Treasury just did you a favorPfizer ($PFE) and Allergan ($AGN) may feel pained by the collapse of their $160 billion merger. But when the U.S. Treasury cracked down on the deal with new tax-inversion rules, it may have done the t2016/4/7
-
AstraZeneca and Takeda DPP-4 inhibitors get another warning added to their labelsThere is more bad news for DPP-4 inhibitor diabetes drugs saxagliptin and alogliptin from AstraZeneca ($AZN) andTakeda. TheFDAhas tightened its regulatory grip on the Type 2 diabetes meds, insisting t2016/4/7
-
Pfizer escapes hundreds of lawsuits alleging birth defects tied to ZoloftPfizer ($PFE) chalked up a big win in its courtroom saga over alleged birth defects tied to its antidepressantZoloft. A federal judge agreed to dismiss the vast majority of claims against the company2016/4/6
-
Allergan ushers #ActuallySheCan campaign onto Tribeca festival screensAllergan ($AGN) is taking its hashtag-heavy, emoji-laden female empowerment campaign, #ActuallySheCan, to the Tribeca Film Festival. Three women directors created films featuring three women aiming at2016/4/6